Genetic and metabolic hallmarks of clear cell renal cell carcinoma
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Clear cell renal cell carcinoma (ccRCC) is a malignancy characterized by deregulated hypoxia-inducible factor signaling, mutation of several key chromatin modifying enzymes, and numerous alterations in cellular metabolism. Pre-clinical studies have historically been limited to cell culture models, however, the identification of critical tumor suppressors and oncogenes from large-scale patient sequencing data has led to several new genetically engineered mouse models with phenotypes reminiscent of ccRCC. In this review, we summarize recent literature on these topics and discuss how they inform targeted therapeutic approaches for the treatment of ccRCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451
RetractedIntratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 3×
“For example, gene expression patterns associated with both good and poor prognoses can be found within the same tumor, and roughly 2/3rd of all somatic mutations are not detectable in every sequenced region [23].”
BackgroundThe emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
The Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150 · cited 1×
“Although an inefficient means of ATP generation relative to oxidative phosphorylation, aerobic glycolysis in cancer cells occurs at a rate much higher than in nonproliferative cells [67].”
BackgroundNeoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233 · cited 1×
“It is believed that enhanced glycolysis benefits tumors through several mechanisms, one being the generation of building blocks for nucleotides, proteins, and lipids through pathways branching from glycolytic intermediates [65].”
BackgroundMotzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · cited 1×
“patients whose disease progressed after receiving either RTK- or VEGF-targeted therapy found that everolimus was effective in prolonging progression-free survival compared with placebo control [100].”
BackgroundReductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791 · cited 1×
“In ccRCC, metabolism of glutamine-derived α-ketoglutarate to citrate by reductive carboxylation fuels lipid synthesis rather than glucose-derived citrate generated by oxidation [81], [82].”
Background
Cited by
Decoder-seq enhances mRNA capture efficiency in spatial RNA sequencing
Cao, J., Zheng, Z., Sun, D., Chen, X., Cheng, R., Lv, T., An, Y., Zheng, J., Song, J., Wu, L., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-02086-y · Cited by 71
“The subtype-specific CNs 1 and 2 had high abundances of proximal tubule epithelial cells and distal tubule epithelial cells, respectively, in line with their different origins 39,40 (Fig.”
(2025) · doi:10.1038/s41467-025-58439-5 · Cited by 21
Metadata
- Authors
- Sanchez, D. J., & Simon, M. C.
- Venue
- Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 1870
- Issue
- 1
- Pages
- 23-31
- ISSN
- 0304-419X (ISSN-L)
- OpenAlex
- W2811408032
- Cited by
- 162
- References
- 34
- FWCI
- 10.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetic and metabolic hallmarks of clear cell renal cell carcinoma. https://app.cochat.ai/papers/10.1016/j.bbcan.2018.06.003
- The paper
- Sanchez, D. J., & Simon, M. C. (2018). Genetic and metabolic hallmarks of clear cell renal cell carcinoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2018.06.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.